Ruxolitinib Oral Tablet

DRUG5 trials

Sponsors

St. Petersburg State Pavlov Medical University, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Grupo Cooperativo de Hemopatías Malignas, Azienda USL Toscana Nord Ovest, Baylor Research Institute

Conditions

Acute GVHDBreast CancerCOVID-19Graft Vs Host DiseaseMetastatic Triple-Negative Breast CarcinomaSevere Acute Respiratory Syndrome Coronavirus 2

Early Phase 1

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

RecruitingNCT06008275

Baylor Research InstituteBreast Cancer, Metastatic Triple-Negative Breast Carcinoma

Start: 2024-09-16End: 2026-12-31Target: 20Updated: 2025-11-07

Phase 1

Treatment of SARS Caused by COVID-19 With Ruxolitinib

CompletedNCT04334044

Grupo Cooperativo de Hemopatías MalignasCOVID-19, Severe Acute Respiratory Syndrome Coronavirus 2

Start: 2020-09-01End: 2021-04-30Updated: 2021-07-07

Phase 2

Ruxolitinib for Steroid-refractory GVHD

CompletedNCT02997280

St. Petersburg State Pavlov Medical UniversityGraft Vs Host Disease

Start: 2016-08-31End: 2019-04-30Updated: 2019-04-05

Ruxolitinib and Steroid As First Line Therapy for Acute GVHD

TerminatedNCT03701698

Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineAcute GVHD

Start: 2018-11-01End: 2024-09-20Updated: 2024-10-01

Unknown Phase

Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection

Azienda USL Toscana Nord OvestSevere Acute Respiratory Syndrome Coronavirus 2

Start: 2020-04-25End: 2020-05-31Target: 13Updated: 2020-04-24

Related Papers

Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol

Frontiers in Medicine2020-08-0454 citations

COVID-19 SARS Treatment with Ruxolitinib; Ongoing Trial and Method

Latin American Journal of Clinical Sciences and Medical Technology2020-05-191 citations

Long-term outcomes of ruxolitinib therapy in steroid-refractory graft-versus-host disease in children and adults.

2020-02-1825 citations

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

BMC Cancer2018-11-1954 citations